Scarica l'app Stockscreener
331.81
0.54%
1.79
Pre-mercato:
328.01
-3.80
-1.15%
Precedente Chiudi:
$330.02
Aprire:
$333.53
Volume 24 ore:
674.34K
Relative Volume:
1.62
Capitalizzazione di mercato:
$9.25B
Reddito:
$7.46M
Utile/perdita netta:
$-303.27M
Rapporto P/E:
-24.64
EPS:
-13.4668
Flusso di cassa netto:
$-249.12M
1 W Prestazione:
-1.72%
1M Prestazione:
+4.96%
6M Prestazione:
+80.76%
1 anno Prestazione:
+765.22%
Intervallo 1D:
$327.89
$341.26
Intervallo di 1 settimana:
$317.92
$353.00
Portata 52W:
$35.21
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Nome
Praxis Precision Medicines Inc
Settore
Industria
Telefono
617-300-8460
Indirizzo
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
331.81 | 9.20B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
435.17 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.77 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.28 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
284.84 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
310.75 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Strong Buy |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-02-02 | Iniziato | Wells Fargo | Equal Weight |
| 2025-12-15 | Reiterato | Oppenheimer | Outperform |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-03 | Reiterato | H.C. Wainwright | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-08-05 | Iniziato | Oppenheimer | Outperform |
| 2024-06-24 | Iniziato | Needham | Buy |
| 2024-06-18 | Iniziato | Guggenheim | Buy |
| 2024-05-01 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-19 | Iniziato | Truist | Buy |
| 2022-06-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | William Blair | Outperform |
| 2020-11-11 | Iniziato | Wedbush | Outperform |
| 2020-11-10 | Iniziato | Cowen | Outperform |
| 2020-11-10 | Iniziato | Evercore ISI | Outperform |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
Praxis Precision Medicines Maps High-Stakes Launch Path - TipRanks
Wedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX) - Yahoo Finance Singapore
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen - Insider Monkey
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $795 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $166 to $1,245 - Moomoo
Number of shareholders of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Praxis Precision Medicines Q1 Earnings Call Highlights - TradingView
Praxis Precision Medicines, Inc.Common Stock (Nasdaq:PRAX) Stock Quote - FinancialContent
PRAX Maintained by Wedbush -- Price Target Raised to $166.00 - GuruFocus
Deutsche Bank Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Cuts Target Price to $420 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $441 to $1,245 - Moomoo
Praxis Precision Medicines, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $420 From $444, Maintains Buy Rating - marketscreener.com
PRAX Reiterated by BTIG -- Price Target Maintained at $843 - GuruFocus
Praxis Precision Medicines, Inc (PRAX): Investor Outlook on a Biotechnology Challenger with 90% Upside Potential - DirectorsTalk Interviews
TD Cowen Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $554 - Moomoo
PRAX Stock Price, Quote & Chart | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
Praxis Precision Medicines Q1 2026: Loss Narrows 12.1% to -$3.20/Share - AlphaStreet
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - Moomoo
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $537 - Moomoo
Jefferies raises Praxis Precision Medicines stock price target on pipeline catalysts - Investing.com UK
Wolfe Research initiates coverage of Praxis Precision Medicines (PRAX) with outperform recommendation - MSN
Earnings call transcript: Praxis Precision beats Q1 2026 EPS forecasts By Investing.com - Investing.com Australia
Earnings call transcript: Praxis Precision beats Q1 2026 EPS forecasts - Investing.com
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results - Investing News Network
PRAX: Two NDAs accepted, strong clinical momentum, and $1.4B cash support launches in 2026 - TradingView
Praxis Precision Medicines Q1 2026 Earnings Call Transcript - MarketBeat
Praxis Precision Medicines 1Q 2026: Net loss $(92.6M), EPS $(3.20) — 10-Q Summary - TradingView
Praxis (PRAX) secures $1.4B cash as epilepsy and tremor NDAs advance - Stock Titan
Q1 2026 Praxis Precision Medicines Inc Earnings Call Transcript - GuruFocus
A seizure drug cut monthly seizures 77% as Praxis nears 2 FDA calls - Stock Titan
Press Release: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results - Moomoo
Praxis earnings up next as biotech nears commercial transformation - Investing.com UK
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $795 - Moomoo
FMR LLC holds 7.7% of Praxis Precision Medicines (PRAX) — 2.16M shares - Stock Titan
Price-Driven Insight from (PRAX) for Rule-Based Strategy - Stock Traders Daily
Praxis gives 21 new employees stock awards tied to hiring - Stock Titan
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines Inc expected to post a loss of $3.57 a shareEarnings Preview - TradingView
Praxis Precision Medicines (PRAX.US) will release its earnings report before the market opens on May 7. - Moomoo
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference - The Manila Times
Praxis maps out two investor events in May, starting with Q1 results - Stock Titan
Praxis (PRAX) Aligns Pay With Ulixacaltamide Progress Is Incentive Design Now a Key Edge? - Yahoo Finance
A Look At Praxis Precision Medicines (PRAX) Valuation After Strong Long Term Shareholder Returns - Yahoo Finance
Praxis (NASDAQ: PRAX) details 2026 virtual meeting, director slate and Say-on-Pay - Stock Titan
Vanguard (NASDAQ: PRAX) reports 1.42M shares, 5.09% stake in Praxis - Stock Titan
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $567 - Moomoo
Analysts Project Growth for Praxis Precision Medicines Biotech Stock - HarianBasis.co
Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide - Insider Monkey
Moody Aldrich Partners LLC Buys New Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Pictet Asset Management Holding SA Makes New $71.09 Million Investment in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines Inc Azioni (PRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.70%
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):